Zynex Inc CEO Sandgaard Announces Record Growth in Q2 Results and Future Innovations
Zynex Inc CEO Sandgaard Announces Record Growth in Q2 Results and Future Innovations
Key Takeaways (TLDR)
Zynex Inc achieved a remarkable 20% year-over-year increase in orders, marking the ninth consecutive quarter of record-breaking order numbers.
Zynex Inc reported an 11% year-over-year increase in second-quarter revenue, totaling $49.9 million, and a 20% increase in year-to-date cash flow from operations, reaching $3.2 million.
Zynex Inc's pain management devices are prescribed for various conditions, from post-surgical recovery to general pain management, by a diverse group of medical professionals, including surgeons, general practitioners, and chiropractors.
Zynex Inc is developing new monitoring devices, including a pulse oximeter based on laser technology for more accurate blood measurements, which could also detect sepsis.
Why it Matters
This news matters as it demonstrates the strong financial performance and innovation efforts of Zynex Inc, which could potentially impact the medical device market and benefit patients seeking advanced pain management solutions.
Summary
Zynex Inc CEO Thomas Sandgaard announced the company's financial and operational results for the second quarter, with a remarkable 20% year-over-year increase in orders and an 11% increase in second-quarter revenue. The company emphasized ongoing efforts to secure FDA approvals for next-generation devices in pain management and provided guidance for the third quarter, expecting revenue to reach at least $50.0 million. Zynex's pain management devices are prescribed for various conditions, and the company is developing new monitoring devices to potentially capture significant market share.
This news story relied on a press release distributed by News Direct. Blockchain Registration, Verification & Enhancement provided by NewsRamp™. The source URL for this press release is Zynex Inc CEO Sandgaard Announces Record Growth in Q2 Results and Future Innovations.